For Grade 2 infusion reactions, treatment with this product may be continued or temporarily suspended under close monitoring; prophylactic use of antipyretic analgesic and anti-inflammatory drugs and antihistamines may be considered for subsequent treatment. For Grade 3 infusion reactions, the infusion must be stopped immediately, symptomatic and supportive treatment should be administered, and this product must be permanently discontinued.
Due to potential adverse reactions such as fatigue associated with this product, patients are advised to use caution when driving or operating machinery until it is confirmed that the product does not affect them adversely.
Without compatibility studies, this product must not be mixed with other pharmaceutical products. This product should not be infused through the same intravenous line as other pharmaceutical products.
